An observational study in Acute Coronary Syndromes, sponsored by Heart Care Foundation. Completed at 203 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-03.
Sponsored by Heart Care Foundation · Observational
This register will evaluate the use of different antithrombotic therapies, combinations of different drugs routinely used during any stage of hospital admission, with their timing, dosage and mode of administration, in patients with a diagnosis of Acute Coronary Syndrome in the Italian Coronary Care Unit during a study period of three weeks
1,461 studies on the registry are indexed under Acute Coronary Syndrome; 267 are open to participants now.
This study's enrollment of 2,597 is above the median of 500 across 561 observational studies indexed under Acute Coronary Syndrome.
Browse Acute Coronary Syndrome studies →Heart Care Foundation is the lead sponsor of 22 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with a diagnosis of Acute Coronary Syndrome consecutively admitted in the Italian Cardiac Care Unit, located in hospitals with and without cardiac cath lab and cardiac surgery, during a period of 3 weeks
Exclusion criteria:
Antithrombotic drugs in patient undergoing percutaneous transluminal coronary angiography, coronary artery bypass graft or no coronary revascularization
Time frame: Participants will be followed for the duration of hospital stay, an expected average period of 7 days
In-hospital ischemic and hemorrhagic events
Time frame: Participants will be followed for the duration of hospital stay, an expected average period of 7 days
Showing the first 100 of 203 sites.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Heart Care Foundation